Basket | Login | Register

 
 
 
 

Clinical trials by country

Clinical Trials Watch

Austria

  1. APECS
  2. CREAD
  3. ENGAGE

Belgium

  1. AMARANTH
  2. APECS
  3. CREAD
  4. EMERGE
  5. GENERATION
  6. JNJ-54861911

Bulgaria

  1. CREAD

Croatia

  1. BREXPIPRAZOLE study (two fixed doses)
  2. CREAD

Czech Republic

  1. MINDSET
  2. CREAD

Denmark

  1. CREAD
  2. ENGAGE
  3. JNJ-54861911

Finland

  1. APECS
  2. CREAD
  3. GENERATION (planned)
  4. JNJ-54861911

France

  1. AMARANTH
  2. APECS
  3. BREXPIPRAZOLE study (flexible dosing)
  4. CREAD
  5. EMERGE
  6. ENGAGE
  7. GENERATION (planned)
  8. JNJ-54861911
  9. MINDSET

Germany

  1. AMARANTH
  2. APECS
  3. BREXPIPRAZOLE study (two fixed doses)
  4. CREAD
  5. EMERGE
  6. ENGAGE
  7. GENERATION (planned)
  8. JNJ-54861911
  9. MINDSET

Hungary

  1. AMARANTH
  2. APECS
  3. CREAD

Italy

  1. AMARANTH
  2. APECS
  3. CREAD
  4. EMERGE
  5. ENGAGE
  6. GENERATION (planned)
  7. MINDSET

Lithuania

  1. CREAD

Netherlands

  1. APECS
  2. EMERGE
  3. GENERATION (planned)
  4. JNJ-54861911

Norway

  1. APECS

Poland

  1. AMARANTH
  2. CREAD
  3. EMERGE
  4. MINDSET

Portugal

  1. CREAD
  2. ENGAGE

Romania

  1. AMARANTH

Russia

  1. BREXPIPRAZOLE study (flexible dosing)
  2. BREXPIPRAZOLE study (two fixed doses)
  3. CREAD

Serbia

  1. BREXPIPRAZOLE study (two fixed doses)

Slovakia

  1. MINDSET

Slovenia

  1. BREXPIPRAZOLE study (flexible dosing)
  2. CREAD

Spain

  1. AMARANTH
  2. APECS
  3. BREXPIPRAZOLE study (two fixed doses)
  4. CREAD
  5. EMERGE
  6. ENGAGE
  7. GENERATION (planned)
  8. JNJ-54861911
  9. MINDSET

Sweden

  1. CREAD
  2. EMERGE
  3. JNJ-54861911

Switzerland

  1. APECS
  2. CREAD
  3. EMERGE
  4. GENERATION (planned)
  5. JNJ-54861911

Turkey

  1. CREAD

Ukraine

  1. BREXPIPRAZOLE study (flexible dosing)
  2. CREAD

UK

  1. AMARANTH
  2. APECS
  3. CREAD
  4. ENGAGE
  5. GENERATION (planned)
  6. JNJ-54861911
  7. MINDSET

 

 
 

Last Updated: Friday 03 February 2017

 

 
 

Options